Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4/nuclear factor kappa B pathways

Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4/nuclear factor kappa B pathways

Context Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease, can develop into metabolic associated fatty liver disease (MAFLD). Gypenosides (GP), the main phytochemical component of Gynostemma pentaphylla (Thunb.) Makino (Cucurbitaceae), have been applied for treatment o...

Full description

Bibliographic Details
Main Authors: Shuhua Shen, Kungen Wang, Yihui Zhi, Yue Dong
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Pharmaceutical Biology
Subjects:
MAFLD
intestinal mucosa damage
hepatic function impairment
Online Access:https://www.tandfonline.com/doi/10.1080/13880209.2022.2126503

Internet

https://www.tandfonline.com/doi/10.1080/13880209.2022.2126503

Similar Items